TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors

Last updated: June 22, 2024
Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Overall Status: Active - Recruiting

Phase

1

Condition

N/A

Treatment

TCR-T cells

Clinical Study ID

NCT03778814
ZZTCRT-006
  • Ages 18-75
  • All Genders

Study Summary

Tumor organoids and TILs (and/or peripheral T cells) cultures will be established from fresh tissure of lung cancer and other solid tumors. Coculture will be utilized to screen tumor-responsive T cells which are further selected for monoclonal expansion and TCR cloning for engineered reconstitution of TCR-T cells. After verification by multiple in vitro and in vivo studies, a large number of TCR-T cells will be introduced back into the patients via vein, artery or fine needle punctured to the tumor, or combinations. In this phase I study, the safety, tolerance and preliminary efficacy of the TCR-T cell immunotherapy on human will firstly be assessed.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. patients with advanced lung tumor or other solid tumor where biopsy is obtainable

  2. Life expectancy >12 weeks

  3. Child-Pugh-Turcotte score <7

  4. Adequate heart,lung,liver,kidney function

  5. Available autologous transduced T cells with greater than or equal to 20% expressionof targeted TCR sequences determined by flow-cytometry and killing of tumor cellsgreater than or equal to 20% in cytotoxicity assay

  6. Informed consent explained to, understood by and signed by patient/ guardian.Patient/guardian given copy of informed consent. -

Exclusion

Exclusion Criteria:

  1. Had accepted gene therapy before;

  2. Tumor size more than 25cm;

  3. Severe virus infection such as HBV, HCV, HIV, et al

  4. Known HIV positivity

  5. History of lung transplantation

  6. Active infectious disease related to bacteria, virus,fungi,et al

  7. Other severe diseases that the investigators consider not appropriate;

  8. Pregnant or lactating women

  9. Systemic steroid treatment (greater than or equal to 0.5 mg prednisoneequivalent/kg/day)

  10. Other conditions that the investigators consider not appropriate.

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: TCR-T cells
Phase: 1
Study Start date:
December 01, 2018
Estimated Completion Date:
December 30, 2036

Study Description

  1. Choose appropriate patients with KK-LC-1 expression in advanced lung cancer or other solid tumors and matched MHC-A11 typing, with written consent for this study; For cancer without expression of KK-LC-1, fresh tumor tissue should be obtained for RNA/DNA sequencing to computationally identify neoantigen peptides that can be captured by specifically personizedly synthesized poly-MHCI which can be further used to fish appropriate T cells from the patient.

  2. Perform biopsy to obtain tissue from tumor/lymph node for organoids, TILs, DC and T cells culture, coculture to screening anti-tumor T cells, establish and select monoclonal T cells for TCR cloning;

  3. Clone TCR sequence that targets KK-LC-1 or neoantigens; collect PBMCs from the blood of the patients, isolate and activate the T cells and generate the TCR-T cells;

  4. Test the quality and killing activity of the TCR-T cells in vitro and then transplant back the patients via systemic (vein and/or artery) or local injections, and follow up closely to collect related clinical data as needed;

  5. Evaluate the clinical results as needed.

Connect with a study center

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guanzhou, Guangdong 51260
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.